HUE068300T2 - Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra - Google Patents
Pridopidin törékeny X szindróma kezelésében történõ alkalmazásraInfo
- Publication number
- HUE068300T2 HUE068300T2 HUE18741607A HUE18741607A HUE068300T2 HU E068300 T2 HUE068300 T2 HU E068300T2 HU E18741607 A HUE18741607 A HU E18741607A HU E18741607 A HUE18741607 A HU E18741607A HU E068300 T2 HUE068300 T2 HU E068300T2
- Authority
- HU
- Hungary
- Prior art keywords
- pridopidine
- fragile
- syndrome
- treatment
- Prior art date
Links
- 208000001914 Fragile X syndrome Diseases 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448595P | 2017-01-20 | 2017-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE068300T2 true HUE068300T2 (hu) | 2024-12-28 |
Family
ID=62908348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18741607A HUE068300T2 (hu) | 2017-01-20 | 2018-01-18 | Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11234973B2 (enExample) |
| EP (1) | EP3570940B1 (enExample) |
| JP (1) | JP7114604B2 (enExample) |
| CN (1) | CN110505902B (enExample) |
| AU (1) | AU2018210145B2 (enExample) |
| BR (1) | BR112019015000A2 (enExample) |
| CA (1) | CA3050700C (enExample) |
| DK (1) | DK3570940T3 (enExample) |
| ES (1) | ES2972205T3 (enExample) |
| HU (1) | HUE068300T2 (enExample) |
| IL (1) | IL268125B2 (enExample) |
| PL (1) | PL3570940T3 (enExample) |
| WO (1) | WO2018136600A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX2019002190A (es) | 2016-08-24 | 2019-09-11 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para tratar distonías. |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| AU2018329628B2 (en) | 2017-09-08 | 2021-04-22 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| EP4088721B1 (en) * | 2020-01-08 | 2025-09-17 | Neuroventi | Composition for treating fragile x syndrome or related developmental disorders, comprising lisuride compound as active ingredient |
| CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| AU2005293754B2 (en) | 2004-10-13 | 2011-07-21 | Teva Pharmaceuticals International Gmbh | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine |
| DK2146961T3 (da) | 2007-04-12 | 2014-04-28 | Ivax Int Gmbh | N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler |
| WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| CN103080343A (zh) | 2010-07-02 | 2013-05-01 | Skf公司 | 机械部件和用于表面硬化的方法 |
| AU2011298382A1 (en) | 2010-09-03 | 2013-05-02 | Teva Pharmaceuticals International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| BR112013018898B1 (pt) * | 2011-01-27 | 2021-10-05 | Neuren Pharmaceuticals Limited | Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo |
| KR20140075703A (ko) | 2011-09-07 | 2014-06-19 | 아이백스 인터내셔널 게엠베하 | 프리도피딘 하이드로클로라이드의 다형 형태 |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| HK1211483A1 (en) * | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| KR102316933B1 (ko) | 2013-06-21 | 2021-10-26 | 프리레니아 뉴로테라퓨틱스 엘티디. | 헌팅턴병 치료를 위한 프리도피딘의 용도 |
| DK3096759T3 (da) | 2014-01-22 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Pridopidinformuleringer med modificeret frigivelse |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| JP2018505147A (ja) | 2014-12-22 | 2018-02-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジンのｌ−酒石酸塩 |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
-
2018
- 2018-01-18 HU HUE18741607A patent/HUE068300T2/hu unknown
- 2018-01-18 ES ES18741607T patent/ES2972205T3/es active Active
- 2018-01-18 WO PCT/US2018/014169 patent/WO2018136600A1/en not_active Ceased
- 2018-01-18 BR BR112019015000A patent/BR112019015000A2/pt not_active Application Discontinuation
- 2018-01-18 AU AU2018210145A patent/AU2018210145B2/en active Active
- 2018-01-18 JP JP2019539958A patent/JP7114604B2/ja active Active
- 2018-01-18 IL IL268125A patent/IL268125B2/en unknown
- 2018-01-18 DK DK18741607.8T patent/DK3570940T3/da active
- 2018-01-18 PL PL18741607.8T patent/PL3570940T3/pl unknown
- 2018-01-18 CN CN201880007913.2A patent/CN110505902B/zh active Active
- 2018-01-18 CA CA3050700A patent/CA3050700C/en active Active
- 2018-01-18 EP EP18741607.8A patent/EP3570940B1/en active Active
-
2019
- 2019-07-17 US US16/514,167 patent/US11234973B2/en active Active
-
2022
- 2022-01-31 US US17/588,403 patent/US20220202798A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018136600A1 (en) | 2018-07-26 |
| IL268125A (en) | 2019-09-26 |
| US11234973B2 (en) | 2022-02-01 |
| CA3050700C (en) | 2023-10-03 |
| PL3570940T3 (pl) | 2024-06-17 |
| ES2972205T3 (es) | 2024-06-11 |
| BR112019015000A2 (pt) | 2020-04-07 |
| IL268125B2 (en) | 2023-04-01 |
| JP2020514313A (ja) | 2020-05-21 |
| IL268125B (en) | 2022-12-01 |
| US20190336488A1 (en) | 2019-11-07 |
| AU2018210145B2 (en) | 2023-06-29 |
| AU2018210145A1 (en) | 2019-08-29 |
| CN110505902B (zh) | 2022-11-11 |
| CN110505902A (zh) | 2019-11-26 |
| JP7114604B2 (ja) | 2022-08-08 |
| EP3570940A4 (en) | 2020-10-28 |
| DK3570940T3 (da) | 2024-02-19 |
| EP3570940A1 (en) | 2019-11-27 |
| CA3050700A1 (en) | 2018-07-26 |
| EP3570940B1 (en) | 2023-12-13 |
| US20220202798A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273495A (en) | Treatment of fragile X syndrome with cannabidiol | |
| GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
| PL3570940T3 (pl) | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x | |
| IL258972A (en) | Thin and flexible absorbent items | |
| IL250016A0 (en) | Antisense oligonucleotides for the treatment of type 2 syndrome | |
| IL258962A (en) | Thin and flexible absorbent items | |
| GB2574762B (en) | Absorbent article | |
| GB201621480D0 (en) | Use of cannabinoids in the treatment of angelman syndrome | |
| IL258963A (en) | Thin and flexible absorbent items | |
| GB2574984B (en) | Thong-style absorbent article | |
| IL272163B1 (en) | Imatelastat for use in the treatment of myelodysplastic syndrome | |
| SG11202004898VA (en) | Underpants-shaped absorbent article | |
| GB2581058B (en) | Absorbent article | |
| SG11202000921XA (en) | Absorbent article | |
| GB2581054B (en) | Absorbent article | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| ZA202003100B (en) | Absorbent article component | |
| PL3716927T3 (pl) | Wyrób chłonny | |
| HUE066511T2 (hu) | Készítmények hunter-szindróma kezelésére | |
| GB2581084B (en) | Absorbent article | |
| GB202017373D0 (en) | Absorbent article | |
| SG11202000922VA (en) | Absorbent article | |
| PL3691592T3 (pl) | Wyrób chłonny | |
| CA186506S (en) | Absorbent article | |
| CA186507S (en) | Absorbent article |